Settlement of Apple Health hepatitis C lawsuit receives court’s preliminary approval; HCA mails notice to affected clients

Thu, 01/19/2017

In May 2016, a U.S. District Court judge directed the Washington State Health Care Authority (HCA) to provide coverage of hepatitis C direct-acting antiviral drugs to Apple Health (Medicaid) clients with hepatitis C without using the client’s fibrosis score to determine medical necessity. HCA, administrator of Washington’s Apple Health program, complied immediately.

The ruling stemmed from a class-action lawsuit filed on behalf of current and former Apple Health clients with hepatitis C.

In January 2017, the judge preliminarily approved settlement of the Apple Health lawsuit. The agreement is available on the HCA website.

As part of the agreement, HCA is mailing notices to about 29,000 current and former Apple Health clients to inform them of drug treatments that could be available to them. The notices also explain these clients’ legal rights and how they may request additional information.

The judge approved separate notices to three different groups of Apple Health clients. Links to the notices are provided below: